Valneva, Pfizer: 6-Month Antibody Persistence Data in Children and Adults for Lyme Vaccine Candidate

 

• Antibody levels remained above baseline sixmonths aftercompletion ofa three-dose(Month 0-2-6)or a two-dose (Month 0-6) vaccination schedule
• Higher antibody levels were observedinthe three-dosevaccination schedule versus the two-dose vaccination schedule, further validating the use of this schedule in the ongoing Phase 3 study
• There were nosafety concerns observed in this six-monthobservational follow up

https://www.biospace.com/article/releases/valneva-and-pfizer-report-six-month-antibody-persistence-data-in-children-and-adults-for-lyme-disease-vaccine-candidate/